Combinations of three chemotherapeutic agents and two chemotherapeutic agents plus a targeted biologic agent in the treatment of advanced non small-cell lung cancer.

Combinations of three chemotherapeutic agents and two chemotherapeutic agents plus a targeted biologic agent in the treatment of advanced non small-cell lung cancer. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Combinations of three chemotherapeutic agents and two chemotherapeutic agents plus a targeted biologic agent in the treatment of advanced non small-cell lung cancer. Abstract Text:

P A Bunn,K Kelly,

Lung cancer is the most common cause of cancer death in the world. In the United States, more than 28% of all cancer deaths are from lung cancer. In the past decade, a number of new drugs were introduced into the treatment of lung cancer including taxanes, gemcitabine, vinorelbine, and irinotecan. Combinations of one of these drugs with cisplatin, with carboplatin, or with one another were shown to be superior to best supportive care, to single-agent cisplatin, and in some instances, to a podophyllotoxin and cisplatin. Comparisons of the various two-drug combinations showed that they are equivalent in efficacy although there are differences in convenience, cost, and toxicity. Many of these two-drug combinations are less toxic than older combinations, which allowed for the development of three-drug combinations that could be given in full dose and with acceptable toxicity. Phase II trials of several three-drug combinations including carbo-platin/paclitaxel/gemcitabine and cisplatin/vinorelbine/gemcitabine showed response rates and survival rates that were somewhat higher than anticipated with a two-drug combination. These data led to three randomized trials of a doublet combination versus a triplet combination. Each of these trials showed a higher response rate and higher toxicity rates with the triplet combination. The toxicity rates were still acceptable with the triplet combinations. The survival was also superior in the triplet arms of each of the randomized trials. Unfortunately, the sample size in each of these studies was small and the survival differences are not statistically significant. Therefore, additional larger randomized trials are sorely needed. During the past decade, new molecularly targeted agents were introduced into the treatment of lung cancer and completed phase I and II trials. Objective responses were noted with many of these new agents. Several combinations of doublet chemotherapy with a new targeted agent have completed phase II trials with encouraging results. Some of these new triplets are now in phase III randomized trials.

Combinations of three chemotherapeutic agents and two chemotherapeutic agents plus a targeted biologic agent in the treatment of advanced non small-cell lung cancer. Publishing Authors By Initials

PA Bunn,K Kelly,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Combinations of three chemotherapeutic agents and two chemotherapeutic agents plus a targeted biologic agent in the treatment of advanced non small-cell lung cancer. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Clinical lung cancer

VOLUME: 2 Suppl 1

Page Numbers: S23-8

Journal Abbreviation:

ISSN: 1525-7304

DAY: 16

MONTH: Dec

YEAR: 2000

Combinations of three chemotherapeutic agents and two chemotherapeutic agents plus a targeted biologic agent in the treatment of advanced non small-cell lung cancer. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 100893225

Combinations of three chemotherapeutic agents and two chemotherapeutic agents plus a targeted biologic agent in the treatment of advanced non small-cell lung cancer. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Combinations of three chemotherapeutic agents and two chemotherapeutic agents plus a targeted biologic agent in the treatment of advanced non small-cell lung cancer. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Combinations of three chemotherapeutic agents and two chemotherapeutic agents plus a targeted biologic agent in the treatment of advanced non small-cell lung cancer.

AFFILIATION: Northwestern University Medical School, Evanston, Illinois; e-mail: paul.bunn@uchsc.edu

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Clin Lung Cancer

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Combinations of three chemotherapeutic agents and two chemotherapeutic agents plus a targeted biologic agent in the treatment of advanced non small-cell lung cancer Related Publications

• "What will happen if I tell you?" Battered Latina women's experiences of health care.
• A review of bacterial pathogens in Ctenocephalides felis in New Zealand.
• Alpha- and gamma-tocopherol plasma and urinary biokinetics following alpha-tocopherol supplementation.
• Amide-to-E-olefin versus amide-to-ester backbone H-bond perturbations: Evaluating the O-O repulsion for extracting H-bond energies.
• Berkelic acid, a novel spiroketal with selective anticancer activity from an acid mine waste fungal extremophile.
• Changes in neuropeptide Y protein expression following photothrombotic brain infarction and epileptogenesis.
• Chemical chaperones and permissive temperatures alter localization of Gaucher disease associated glucocerebrosidase variants.
• Combinations of three chemotherapeutic agents and two chemotherapeutic agents plus a targeted biologic agent in the treatment of advanced non small-cell lung cancer.
• Depressive symptomatology among HIV-positive women in the era of HAART: a stress and coping model.
• Developmental aspects of adipose tissue in GH receptor and prolactin receptor gene disrupted mice: site-specific effects upon proliferation, differentiation and hormone sensitivity.
• Evaluation of voiding dysfunction and measurement of bladder volume.
• Fatty acid composition of habitual diet.
• Gem protein signaling and regulation.
• Geographical variation in selection, from phenotypes to molecules.
• Insulin-resistant heart exhibits a mitochondrial biogenic response driven by the peroxisome proliferator-activated receptor-alpha/PGC-1alpha gene regulatory pathway.
• Isofagomine- and 2,5-anhydro-2,5-imino-D-glucitol-based glucocerebrosidase pharmacological chaperones for Gaucher disease intervention.
• Mechanisms of insulin-induced relaxation of the canine proximal stomach after proximal gastric vagotomy.
• Microvascular blood flow dynamics associated with photodynamic therapy, pulsed dye laser irradiation and combined regimens.
• Modeling Shear Damage to Suspended CHO Cells during Cross-Flow Filtration.
• Oxygen cost, walking speed, and perceived exertion in children with cerebral palsy when walking with anterior and posterior walkers.
• Plasma RRR-alpha-tocopherol concentrations are lower in smokers than in non-smokers after ingestion of a similar oral load of this antioxidant vitamin.
• Predictors of aggressive behaviors among rural middle school youth.
• R104H may suppress transthyretin amyloidogenesis by thermodynamic stabilization, but not by the kinetic mechanism characterizing T119 interallelic trans-suppression.
• The interaction between eating disorders and celiac disease: an exploration of 10 cases.
• The oxidative stress metabolite 4-hydroxynonenal promotes Alzheimer protofibril formation.
• The relationship between pressure flow studies and ultrasound-estimated bladder wall mass.
• Update on Clostridium difficile associated disease.
• Visual response to time-dependent stimuli. I. Amplitude sensitivity measurements.
• emb-4 is a conserved gene required for efficient germline-specific chromatin remodeling during Caenorhabditis elegans embryogenesis.
• gamma-Tocopherol biokinetics and transformation in humans.